Pharmacyclics, Inc. - Product Pipeline Review - 2015

Date: May 27, 2015
Pages: 52
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P253B0B67F7EN
Leaflet:

Download PDF Leaflet

Pharmacyclics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Pharmacyclics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Pharmacyclics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmacyclics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Pharmacyclics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharmacyclics, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharmacyclics, Inc.’s pipeline products
Reasons to buy
  • Evaluate Pharmacyclics, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharmacyclics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharmacyclics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharmacyclics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmacyclics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharmacyclics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Pharmacyclics, Inc. Snapshot
Pharmacyclics, Inc. Overview
Key Information
Key Facts
Pharmacyclics, Inc. - Research and Development Overview
Key Therapeutic Areas
Pharmacyclics, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pharmacyclics, Inc. - Pipeline Products Glance
Pharmacyclics, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Pharmacyclics, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Pharmacyclics, Inc. - Drug Profiles
ibrutinib
Product Description
Mechanism of Action
R&D Progress
PCI-27483
Product Description
Mechanism of Action
R&D Progress
abexinostat hydrochloride
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit BTK for Autoimmune Disorders and Rheumatoid Arthritis
Product Description
Mechanism of Action
R&D Progress
Pharmacyclics, Inc. - Pipeline Analysis
Pharmacyclics, Inc. - Pipeline Products by Target
Pharmacyclics, Inc. - Pipeline Products by Route of Administration
Pharmacyclics, Inc. - Pipeline Products by Molecule Type
Pharmacyclics, Inc. - Pipeline Products by Mechanism of Action
Pharmacyclics, Inc. - Recent Pipeline Updates
Pharmacyclics, Inc. - Dormant Projects
Pharmacyclics, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
PCI-45292
Pharmacyclics, Inc. - Company Statement
Pharmacyclics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Pharmacyclics, Inc., Key Information
Pharmacyclics, Inc., Key Facts
Pharmacyclics, Inc. - Pipeline by Indication, 2015
Pharmacyclics, Inc. - Pipeline by Stage of Development, 2015
Pharmacyclics, Inc. - Monotherapy Products in Pipeline, 2015
Pharmacyclics, Inc. - Partnered Products in Pipeline, 2015
Pharmacyclics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Pharmacyclics, Inc. - Phase III, 2015
Pharmacyclics, Inc. - Phase II, 2015
Pharmacyclics, Inc. - Phase I, 2015
Pharmacyclics, Inc. - Pipeline by Target, 2015
Pharmacyclics, Inc. - Pipeline by Route of Administration, 2015
Pharmacyclics, Inc. - Pipeline by Molecule Type, 2015
Pharmacyclics, Inc. - Pipeline Products by Mechanism of Action, 2015
Pharmacyclics, Inc. - Recent Pipeline Updates, 2015
Pharmacyclics, Inc. - Dormant Developmental Projects,2015
Pharmacyclics, Inc. - Discontinued Pipeline Products, 2015
Pharmacyclics, Inc., Subsidiaries

LIST OF FIGURES

Pharmacyclics, Inc. - Pipeline by Top 10 Indication, 2015
Pharmacyclics, Inc. - Pipeline by Stage of Development, 2015
Pharmacyclics, Inc. - Monotherapy Products in Pipeline, 2015
Pharmacyclics, Inc. - Partnered Products in Pipeline, 2015
Pharmacyclics, Inc. - Pipeline by Top 10 Target, 2015
Pharmacyclics, Inc. - Pipeline by Top 10 Route of Administration, 2015
Pharmacyclics, Inc. - Pipeline by Top 10 Molecule Type, 2015
Pharmacyclics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


GenSpera, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 27 pages
Osel Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 20 pages
Quest PharmaTech Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 33 pages
Radius Health, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Aug, 2014 · 29 pages
TissueGene, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 26 pages

Ask Your Question

Pharmacyclics, Inc. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: